心血管手術機器の世界市場、市場規模とシェアの分析 - 成長動向、予測（2025年～2033年）

心血管手術機器市場の動向とサマリー

世界の心血管手術機器の市場規模は、2024年の21億1,000万米ドルから2033年までに28億6,000万米ドルに達すると予測され、2025年～2033年にCAGRで3.45%の成長が見込まれます。急速な技術の進歩、リーズナブルで効率的な技術の増加、低侵襲手術に対する需要の高まりが、この市場の主な促進要因です。

心血管手術機器市場の成長促進要因

心血管疾患の有病率の増加

心血管機器市場の主な成長促進要因の1つは、心不全や冠動脈疾患（CAD）などの慢性心血管系疾患の有病率の増加です。冠動脈ステントや心臓ステントは、もっとも重要な心血管機器の1つです。これらの機器は、心房細動、冠動脈疾患、心臓発作、動脈狭窄など、致命的な心疾患の治療に役立ちます。先進の心臓機器に対する世界のニーズは、心臓疾患の頻度によって高まっています。

2023年11月に発表された米国疾病予防管理センター（CDC）のデータによると、2022年に米国の成人の4.9%が冠動脈性心疾患の診断を受けました。さらに、心血管疾患は2022年の死亡者数のうち69万5,547人を占め、米国における死因の第1位となっています。世界保健機関（WHO）は、心疾患が年間1,790万人の命を奪うと推定しています。

さらに、市場の拡大には、規制機関による革新的な機器の認可の増加が大きく寄与しています。市場は、発展途上地域の幅広い人々が心血管機器を利用できるようにするために国家機関が実施する数多くの取り組みによって、予測期間に主導される可能性が高いです。

効果的な機器へのアクセスの増加

効果的な心臓機器へのニーズは、世界の心疾患の有病率の明らかな上昇によって高まっています。これらの国々における新技術の採用は、その入手性に起因よるものと考えられます。市場はまた、新興市場におけるこれらの機器の需要の増加に対応するために実施されている取り組みによっても刺激されています。さらに、投資家は中国、メキシコ、インドなどの国々で手頃な価格の心血管機器へのアクセスを増やすことに注力しています。その結果、これは今後数年間、心血管機器市場のかなりのシェアを占めると予測されます。

例えば、UltraLinQ Healthcare Solutionsは、2023年1月のArab Health 2023会議で新しい心臓モニタリングソリューションを発表しました。これは、病院や専門クリニックが、診療所を訪れる患者や自宅から遠隔アクセスできる患者にホルターサービスを提供できるようにするエンドツーエンドのシステムです。

低侵襲技術の採用の増加

市場の拡大の大きな要因の1つは、心血管手術における低侵襲手技の使用の増加です。開腹手術に比べ、低侵襲手技には精巧なイメージングの使用、ロボットによる支援、少ない切開回数などの多くの利点があります。患者は回復期間の短縮、不快感の軽減、感染の可能性の減少、合併症の減少などの恩恵を受けます。ステント、カテーテル、ロボット手術器具のような先進の心血管機器のニーズは、患者が低侵襲手術を好むようになった結果、急増しました。さらに、低侵襲手術は、早期退院、医療費の削減、治療期間の短縮を可能にするため、患者や医療従事者にとって魅力的です。心血管手術機器の市場は、低侵襲心臓手術への動向と継続的な技術の進歩の結果、さらに急速に成長すると予測されます。

心血管手術機器市場の課題

機器の高いコスト

産業の大きな障害の1つは、ペースメーカー、ステント、ロボット手術器具などの先進の心血管機器の高いコストです。これらの機器は製造と研究開発に多額の投資を必要とするため、コストが上昇します。特に医療予算が乏しい低中所得地域では、このようなコストの障壁によって、これらの機器へのアクセスが制限されています。特定の地域の患者が最新でもっとも効率的な医薬品を利用できないことから、心血管治療における格差が生じる可能性があります。さらに、たとえ治療成績が向上しても、こうした地域の医療従事者は、そのコストを主張することが困難であると考える可能性があります。メーカー、政府、医療システムは、費用対効果の高い代替品、価格引き下げ策、創造的な資金調達方法を検討し、アクセスを向上させ、これらの技術をより一般的に利用しやすく、リーズナブルな価格にする必要があります。

当レポートでは、世界の心血管手術機器市場について調査し、成長促進要因と課題、各セグメントの分析、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 心血管手術機器市場

第6章 市場シェア

• 製品タイプ別
• 用途別
• エンドユーザー別
• 国別

第7章 製品タイプ

• 心拍動下手術システム
• 人工心肺
• 心臓アブレーション機器
• 使い捨て灌流用品

第8章 用途

• 先天性心疾患
• 不整脈
• 冠動脈疾患
• うっ血性心不全
• その他

第9章 エンドユーザー

• 病院
• 外来手術センター
• その他

第10章 国

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
  • トルコ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • オーストラリア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 ポーターのファイブフォース分析

第12章 SWOT分析

第13章 主要企業の分析

• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences
• Cardinal Health Inc.
• Medtronic PLC
• GE Healthcare
• LivaNova PLC
• Terumo Corporation

Cardiovascular Surgical Devices Market Trends & Summary

Cardiovascular Surgical Devices market is expected to reach US$ 2.86 billion by 2033 from US$ 2.11 billion in 2024, with a CAGR of 3.45% from 2025 to 2033. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The report Cardiovascular Surgical Devices Market & Forecast covers by Product Type (Beating Heart Surgery Systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposable), Application (Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Others), End-User (Hospitals, Ambulatory Surgical Centers, Others), Country and Company 2025-2033.

Cardiovascular Surgical Devices Industry Overview

The medical equipment and technologies used in the diagnosis, treatment, and management of heart-related illnesses, including arrhythmias, heart valve problems, and coronary artery disease, are the main focus of the cardiovascular surgical devices sector. Stents, heart valves, bypass grafts, pacemakers, defibrillators, and surgical tools are among the main goods. The growing incidence of cardiovascular diseases as a result of aging populations, sedentary lifestyles, and poor diets are some of the factors driving market expansion. Robotic-assisted operations and minimally invasive procedures are examples of technological advancements that have improved patient outcomes while cutting recovery times and medical expenses. Government funding, improvements in diagnostics, and growing healthcare awareness all support industry growth. High expenses, legal restrictions, and the demand for continuous clinical research to improve device efficacy and safety provide difficulties for the sector.

One of the most common illnesses in the world is cardiovascular disease. Cardiovascular disease (CVD) was the top cause of mortality in the United States in January 2024, accounting for 931,578 fatalities, more than all malignancies and chronic respiratory diseases combined, according to the American Heart Association. Cardiovascular devices are therefore essential for precisely identifying and treating heart conditions, which supports market growth. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The market is expanding as a result of the rise in chronic cardiovascular disease cases. The need for cardiovascular devices has grown as a result of a rise in cardiovascular diseases. One of the most important cardiovascular devices is a heart or coronary artery stent. They make it easier to treat heart conditions such heart attacks, coronary disease, atrial fibrillation, and the growth of clogged arteries that are thought to pose a major risk to life. According to a WHO analysis from May 2024, cardiovascular diseases (CVDs) account for over 42.5% of all deaths in Europe each year, or almost 10,000 deaths per day, making them the leading cause of disability and early death. Men are over 2.5 times more likely than women to die from cardiovascular diseases (CVDs), and young people in Eastern Europe and Central Asia (ages 30-69) are at approximately five times the risk of dying from these diseases than their counterparts in Western Europe.

Growth Drivers for the Cardiovascular Surgical Devices Market

Increase in Cardiovascular Disease Prevalence

Plywood's In terms of expenses and medical services, the most common cause of patient growth is heart disease. One of the main factors driving the growth of the cardiovascular devices market is the increase in the prevalence of chronic cardiovascular illnesses like heart failure and coronary artery disease (CAD). Coronary or cardiac stents are among the most important cardiovascular devices. These devices aid in the treatment of potentially fatal cardiac problems, including atrial fibrillation, coronary heart disease, heart attacks, and constricted artery opening. The global need for sophisticated cardiac devices is increased by the frequency of cardiac disorders.

According to Centers for Disease Control and Prevention (CDC) data released in November 2023, 4.9% of adults in the United States received a coronary heart disease diagnosis in 2022. Additionally, cardiovascular illnesses account for 695,547 fatalities in 2022, making them the leading cause of death in the United States. The World Health Organization estimates that heart disease claims 17.9 million lives annually.

Furthermore, the market's expansion is significantly aided by the rise in regulatory bodies' approvals of innovative gadgets. The market will likely be guided over the forecast period by a number of efforts implemented by state bodies to make cardiovascular devices available to a broad population in developing regions.

Growing Accessibility of Effective Devices

The need for effective heart devices is fueled by the apparent rise in the prevalence of heart illnesses worldwide. The adoption of modern technology in these countries can be attributed to their accessibility. The market has also been stimulated by initiatives that have been implemented to meet the growing demand for these devices in emerging markets. Additionally, investors are concentrating on increasing the accessibility of affordable cardiovascular equipment in nations like China, Mexico, India, and others. In consequence, this is anticipated to draw a significant portion of the market for cardiovascular devices in the years to come.

For example, UltraLinQ Healthcare Solutions debuted a new cardiac monitoring solution at the Arab Health 2023 conference in January 2023. It has an end-to-end system that enables hospitals and specialty clinics to provide Holter services to patients who visit their clinics or who can be accessed remotely at home.

Rising Adoption of Minimally Invasive Techniques

One major factor propelling the market's expansion is the growing use of minimally invasive procedures in cardiovascular surgery. Compared to open operations, these techniques have a number of benefits, including the use of sophisticated imaging, robotic help, and fewer incisions. Patients gain from shorter recovery periods, less discomfort, a decreased chance of infection, and fewer complications. The need for sophisticated cardiovascular devices like stents, catheters, and robotic surgical instruments has surged as a result of patients' growing preference for minimally invasive operations. Furthermore, minimally invasive procedures are more appealing to patients and healthcare professionals since they enable faster hospital discharge, lower medical expenses, and shorter treatment durations overall. The market for cardiovascular surgical equipment is anticipated to grow even faster as a result of the trend toward minimally invasive cardiac procedures and ongoing technological advancements.

Challenges in the Cardiovascular Surgical Devices Market

High Cost of Devices

One major obstacle in the industry is the high cost of sophisticated cardiovascular equipment, such as pacemakers, stents, and robotic surgical instruments. The cost of these gadgets rises because they frequently need significant investment in manufacturing, research, and development. Their accessibility is restricted by this cost barrier, especially in areas with low and intermediate incomes where healthcare budgets are tight. Disparities in cardiovascular care may result from patients in certain areas not having access to the newest, most efficient medicines. Furthermore, even with better results, healthcare practitioners in these areas might find it difficult to defend the cost. Manufacturers, governments, and healthcare systems must investigate cost-effective substitutes, price-cutting tactics, and creative financing methods to increase access and make these technologies more generally accessible and reasonably priced.

Regulatory and Compliance Hurdles

The market for cardiovascular surgical devices is severely hampered by regulatory and compliance issues. New device approval is frequently a drawn-out procedure that necessitates comprehensive clinical trials to prove long-term results, safety, and effectiveness. Authorities like the FDA, EMA, or other national agencies have strict regulations that manufacturers must follow. These regulations differ depending on the region. These specifications may lengthen product launch schedules, postponing market entry and reducing potential profits. Development costs may also be raised by the price of carrying out clinical trials, obtaining required data, and satisfying regulatory requirements. These obstacles could hinder innovation, particularly for smaller businesses with fewer resources, and delay the adoption of ground-breaking innovations that could enhance cardiovascular care outcomes for patients.

Cardiac arrhythmia drives demand for devices like pacemakers and defibrillators

Cardiac arrhythmia is pivotal in the cardiovascular surgical devices market because of its prevalence and life-threatening implications. This spurs demand for modern solutions like pacemakers and catheter ablation structures. For instance, in 2024, Boston Scientific Corporation received FDA approval for the FARAPULSE(TM) Pulsed Field Ablation (PFA) System, offering a unique technique for treating drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.

United States Cardiovascular Surgical Devices Market

The high prevalence of cardiovascular diseases (CVDs), an aging population, and growing awareness of heart health are the main factors driving the United States' cardiovascular surgical devices industry, which is among the biggest and most developed in the world. Devices for arrhythmias, heart valve problems, and coronary artery disease, such as pacemakers, defibrillators, robotic surgical instruments, and stents, are important market segments. Technological developments that improve patient outcomes and shorten recovery times, such as bioresorbable devices and minimally invasive operations, are driving market expansion. The adoption of cutting-edge equipment is also made easier in the United States by its well-established healthcare infrastructure, government support, and high healthcare spending rate. High gadget costs, difficulties with regulations, and problems with reimbursement, however, continue to be commercial obstacles. The US continues to be a major force behind the development and marketing of cardiovascular devices worldwide.

An American Heart Association report from January 2024 states that around 2,552 fatalities in the United States are caused by CVD per day. Because of the substantial impact that CVD has on public health, there is an urgent need for efficient management and treatment options in the US market.

Abbott introduced the Abbott HeartMates program in October 2023 to help heart patients by allowing them to connect with others experiencing similar heart health concerns and share their stories. Professional football player Damar Hamlin served as the company's first ambassador at the beginning of the campaign under this program.

Germany Cardiovascular Surgical Devices Market

Due to its sophisticated healthcare system, elderly population, and high prevalence of cardiovascular diseases (CVDs), Germany is one of Europe's largest markets for cardiovascular surgical equipment. The adoption of sophisticated cardiovascular equipment, including as pacemakers, heart valves, stents, and surgical robots, is facilitated by the nation's robust reimbursement regulations and well-established medical infrastructure. Germany's emphasis on innovation, bolstered by a robust research and development environment, makes it easier to introduce innovative technology such as bioresorbable devices and minimally invasive procedures. The market is also growing as a result of the rising need for therapies for arrhythmias, heart failure, and coronary artery disease. Strict regulatory standards, the expensive cost of sophisticated gadgets, and rivalry from other European nations are some of the market's obstacles, nevertheless. Germany is nevertheless a major player in the global market for cardiovascular surgical devices in spite of these obstacles.

Data from a German registry for 2023, which included 168,841 cardiac and vascular surgeries in 77 institutions, was published in January 2024 by The Journal of Thoracic and Cardiovascular Surgery. The unadjusted in-hospital survival rates for 28,996 coronary artery bypass grafts, 39,859 cardiac valve surgeries, and 19,699 pacemaker/ICD implants were 97.6%, 97.7%, and 99.2%, respectively. In addition, 324 heart transplants and 2,982 extracorporeal life support treatments were carried out.

India Cardiovascular Surgical Devices Market

The increasing prevalence of cardiovascular diseases (CVDs) and improved access to healthcare are driving the market for cardiovascular surgical devices in India. Heart disease is becoming more prevalent in the nation as a result of aging populations, urbanization, and shifting lifestyles. Government programs, growing public awareness of heart health, and the development of healthcare infrastructure are important market drivers. Particularly in urban areas, there is a growing need for cardiovascular equipment such as heart valves, pacemakers, stents, and angioplasty instruments. Additionally, as doctors and patients look for better results and faster recovery periods, the use of minimally invasive procedures is increasing. However, obstacles including exorbitant equipment expenses, restricted reimbursement, and restricted availability in remote regions may prevent the industry from growing further. India continues to be a promising market for producers of cardiovascular devices in spite of these obstacles.

In the Indian state of Maharashtra, a decrease in the cost of coronary stents resulted in a 43.0% rise in the number of heart procedures performed, according a study conducted by the Harvard T.H. Chan School of Public Health (HSPH).

Saudi Arabia Cardiovascular Surgical Devices Market

Due to the high prevalence of cardiovascular diseases (CVDs) and significant healthcare investments, the market for cardiovascular surgical equipment is growing quickly in Saudi Arabia. An aging population, sedentary lifestyles, and changing lifestyles are the main causes of the Kingdom's rising heart disease rates. The government's Vision 2030 program, which aims to improve medical technology, expand access to high-quality care, and strengthen healthcare infrastructure, is driving up demand for sophisticated cardiovascular devices like heart valves, pacemakers, defibrillators, and stents. Furthermore, the industry is expanding more quickly due to consumers' increasing preference for minimally invasive procedures. Widespread adoption may be hampered by issues including exorbitant device costs, a lack of local manufacturing, and the requirement for specialized training for sophisticated treatments. Saudi Arabia is still a major Middle Eastern market for cardiovascular surgical devices in spite of this.

The BMC Cardiovascular Diseases article from March 2024 states that 1.6% of Saudi Arabians aged 15 and older had cardiovascular disease. This statistic shows the proportion of people in this age group who suffer from heart disease and other cardiovascular diseases of various kinds. The information highlights an important facet of the nation's health profile and sheds light on the prevalence of cardiovascular diseases among Saudi Arabians.

Cardiovascular Surgical Devices Market Segments

Product Type - Market breakup in 4 viewpoints:

1. Beating Heart Surgery Systems

2. Cardiopulmonary Bypass Equipment

3. Cardiac Ablation Devices

4. Perfusion Disposable

Application - Market breakup in 5 viewpoints:

1. Congenital Heart Defects

2. Cardiac Arrhythmia

3. Coronary Heart Disease

4. Congestive Heart Failure

5. Others

End-User - Market breakup in 3 viewpoints:

1. Hospitals

2. Ambulatory Surgical Centers

3. Others

Country - Market of 25 Countries Covered in the Report:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherland
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Abbott Laboratories

2. Boston Scientific Corporation

3. Edwards Lifesciences

4. Cardinal Health Inc.

5. Medtronic PLC

6. GE Healthcare

7. LivaNova PLC

8. Terumo Corporation

Key Questions Answered in Report:

1. How big is the Cardiovascular Surgical Devices industry?

The global Cardiovascular Surgical Devices market size was valued at US$ 2.11 billion in 2024 and is expected to reach US$ 2.86 billion in 2033.

2. What is the Cardiovascular Surgical Devices growth rate?

The global Cardiovascular Surgical Devices market is expected to expand at a compound annual growth rate (CAGR) of 3.45% from 2025 to 2033.

3. Who are the key players in Cardiovascular Surgical Devices industry?

Some key players operating in the Cardiovascular Surgical Devices market includes Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, GE Healthcare, LivaNova PLC, and Terumo Corporation.

4. What are the factors driving the Cardiovascular Surgical Devices industry?

Ageing populations, rising rates of heart disease, technological developments, minimally invasive procedures, government funding for healthcare, increased public awareness of healthcare issues, and the need for better patient outcomes and surgical efficiency are all factors driving the cardiovascular surgical devices market.

5. Which Region held the largest market share in the Cardiovascular Surgical Devices industry?

North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Cardiovascular Surgical Devices Market report?

Product Type, Application, End User and Countries segment are covered in this report.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Cardiovascular Surgical Devices Market

6. Market Share

• 6.1 By Product Type
• 6.2 By Application
• 6.3 By End User
• 6.4 By Countries

7. Product Type

• 7.1 Beating Heart Surgery Systems
• 7.2 Cardiopulmonary Bypass Equipment
• 7.3 Cardiac Ablation Devices
• 7.4 Perfusion Disposable

8. Application

• 8.1 Congential Heart Defects
• 8.2 Cardiac Arrthymia
• 8.3 Coronary Heart Disease
• 8.4 Congestive Heart Failure
• 8.5 Others

9. End User

• 9.1 Hospitals
• 9.2 Ambulatory Surgical Centers
• 9.3 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherland
  • 10.2.8 Turkey
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Thailand
  • 10.3.6 Malaysia
  • 10.3.7 Indonesia
  • 10.3.8 Australia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 Saudi Arabia
  • 10.5.2 UAE
  • 10.5.3 South Africa

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 Abbott Laboratories
  • 13.1.1 Overview
  • 13.1.2 Recent Development
  • 13.1.3 Revenue Analysis
• 13.2 Boston Scientific Corporation
  • 13.2.1 Overview
  • 13.2.2 Recent Development
  • 13.2.3 Revenue Analysis
• 13.3 Edwards Lifesciences
  • 13.3.1 Overview
  • 13.3.2 Recent Development
  • 13.3.3 Revenue Analysis
• 13.4 Cardinal Health Inc.
  • 13.4.1 Overview
  • 13.4.2 Recent Development
  • 13.4.3 Revenue Analysis
• 13.5 Medtronic PLC
  • 13.5.1 Overview
  • 13.5.2 Recent Development
  • 13.5.3 Revenue Analysis
• 13.6 GE Healthcare
  • 13.6.1 Overview
  • 13.6.2 Recent Development
  • 13.6.3 Revenue Analysis
• 13.7 LivaNova PLC
  • 13.7.1 Overview
  • 13.7.2 Recent Development
  • 13.7.3 Revenue Analysis
• 13.8 Terumo Corporation
  • 13.8.1 Overview
  • 13.8.2 Recent Development
  • 13.8.3 Revenue Analysis